These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33193606)

  • 1. Survival-Associated Alternative Splicing Events and Prognostic Signatures in Pancreatic Cancer.
    Xu L; Pan J; Ding Y; Pan H
    Front Genet; 2020; 11():522383. PubMed ID: 33193606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of alternative splicing events in head and neck squamous cell carcinoma.
    Ding Y; Feng G; Yang M
    Cancer Cell Int; 2020; 20():168. PubMed ID: 32467664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of alternative splicing events and prognostic signatures in breast cancer.
    Han P; Zhu J; Feng G; Wang Z; Ding Y
    BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
    Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
    DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
    Lai J; Yang H; Xu T
    BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
    Liu Y; Jia W; Li J; Zhu H; Yu J
    Front Oncol; 2020; 10():587343. PubMed ID: 33117720
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
    Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
    J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of prognostic alternative splicing signatures in uveal melanoma.
    Xie X; Zheng X; Xie T; Cai J; Yao Y
    Int Ophthalmol; 2021 Apr; 41(4):1347-1362. PubMed ID: 33479809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
    Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
    J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma.
    Yang C; Wu Q; Huang K; Wang X; Yu T; Liao X; Huang J; Zhu G; Gong Y; Han C; Su H; Qin W; Peng T
    Front Oncol; 2019; 9():511. PubMed ID: 31275849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
    Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
    Front Genet; 2020; 11():534. PubMed ID: 32595697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma.
    Zhu L; Wang Z; Sun Y; Giamas G; Stebbing J; Yu Z; Peng L
    Front Oncol; 2021; 11():778637. PubMed ID: 35004299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
    Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
    Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
    [No Abstract]   [Full Text] [Related]  

  • 15. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
    Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
    Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
    Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
    J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Signatures of Alternative Splicing Events in Esophageal Carcinoma Based on TCGA Splice-Seq Data.
    Ye P; Yang Y; Zhang L; Zheng G
    Front Oncol; 2021; 11():658262. PubMed ID: 34676158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
    Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value and Potential Role of Alternative mRNA Splicing Events in Cervical Cancer.
    Shao XY; Dong J; Zhang H; Wu YS; Zheng L
    Front Genet; 2020; 11():726. PubMed ID: 32793282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.